Definium Therapeutics, Inc.

US$33.27As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:DFTXHealthcare
Country USA
PE (Fwd) •••
TSR 7Y CAGR 23.16%
Div yield —
ROE (64.09%)
Biotechnology
Beta (5Y) 2.21
PE TTM —
TSR TTM 134.30%
Mkt cap US$4.470B
ROIC (24.06%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$35
6.64%
378.82%
Hold 11|8|2|7|11
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.75
0.78
0.75
0.73
8.43%
5.94%
3.54%
(5.15%)
Revenue$M
223.1
231.8
243.9
252.0
2.84%
4.42%
7.75%
12.95%
Peers (US$4.470B)
Cap (US$)
PE
4.534B
—
4.470B
9.667x
Capital
TTM
5Y
10Y
Leveragex
3.294
(0.857)
(0.590)
EBIT/Intx
0.821
0.293
0.301
Own earn%
13.31
(131.47)
(134.11)
Sh yield%
25.93
47.07
46.10
Owners
Insiders/Inst%
0.45
33.81
Short interest%
3.95
SBC / revenue%
1.08
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
25
Op margin range%
7–11
$1 testx
0.0
Incr. ROIC%
3